Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 45

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 45
---
, fair to and in the best interests of FutureTech and its stockholders and (ii) to recommend that its stockholders adopt and approve the Merger Agreement and approve the Business Combination contemplated therein, FutureTech’s board of directors considered a range of factors, including but not limited to, the factors discussed below. In light of the number and wide variety of factors, FutureTech’s board of directors did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors it considered in reaching its determination. FutureTech’s board of directors viewed its position as being based on all of the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors. This explanation of FutureTech’s reasons for the Business Combination and all other information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed under the section of this proxy statement/prospectus entitled “ Cautionary Statement Regarding Forward-Looking Statements.” In considering the Business Combination, FutureTech’s board of directors gave considerable weight to the following factors: Due Diligence. FutureTech’s management conducted a due diligence review of Longevity and review of the Targets that included an industry analysis, an analysis of the existing business model of Longevity and the Targets and historical and projected financial results. FutureTech’s management, including its directors and advisors, have many years of experience in both operational management and investment and financial management and analysis and, in the opinion of FutureTech’s Board, were suitably qualified to conduct the due diligence, reviews and other analyses required in connection with the search for a business combination partner. A detailed description of the experience of FutureTech’s executive officers and directors is included in the section of this proxy statement/prospectus entitled “ Management of FutureTech—Directors and Executive Officers.” Large market opportunity.According to the United Nations Population Division, the global population of people ages 65 and above has doubled in the last 25 years, from 392 million in 1997 to 758 million in 2021. Longevity is focused on longevity-related products and services a market with increasing demands from the growing global aging population. The company has the potential to integrate advancement of new technologies across therapeutics, monitoring and digital health into the future platform; Commercial Potential of Candidate Products. Through the acquisition of Aegeria and Ceravast, Longevity will have a series of candidate products under development, including AAT101